SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
Title:
SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
Author:
De Stefano, A. Giuliani, F. Nasti, G. Montesarchio, V. Santabarbara, G. Leo, S. Malapelle, U. Rosati, G. Lolli, I. Tamburini, E. Colombo, A. Santini, D. Silvestro, L. Leone, A. Vitagliano, C. Troncone, G. Sobrero, A. Giannarelli, D. Budillon, A. Avallone, A.